Connect with us

Hi, what are you looking for?

Wednesday, May 31, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


European Parliament launches medical psychedelics action group

The group aims to foster EU-funded research on psychedelics and promote drug policies based on scientific evidence

European Parliament launches 'Action Group' for the medical use of psychedelics
Parliament members met in Strasbourg, France Wednesday and established the Action Group for the Medical Use of Psychedelics. Photo via PAREA

European Parliament members met on Wednesday at their headquarters in France and established a new group dedicated to advancing the field of clinical psychedelics in Europe.

The newly launched Members of the European Parliament (MEP) Action Group for the Medical Use of Psychedelics is intended to serve as an educational resource for policymakers in the European Union (EU) while promoting evidence-based psychedelic science.

The news was announced in the midst of the European Mental Health Week by the Psychedelic Access and Research European Alliance (PAREA) and its Founder Tadeusz Hawrot, who was present at the launch. Hawrot says the group’s ultimate goal is to transform mental health care in Europe.

“By bringing together MEPs across the political spectrum, we will promote the development of sound EU policies and regulations, paving the way for equitable access to affordable and safe novel psychedelic-assisted treatments in the EU,” said MEP Sara Cerdas of Portgual.

PAREA says the World Economic Forum’s Global Risks Report this year identified mental health deterioration as a severe risk to economies and societies.

Read more: Dutch government establishes MDMA research commission

Read more: European Psychiatric Association aligns with PAREA: a multi-organization psychedelic partnership

Additional objectives of the Action Group will include advancing EU-funded research into safe and effective psychedelic medicines and treatments, promoting drug policies based on human rights and scientific evidence to remove barriers hindering the progress of psychedelic research and providing input on current relevant legislative discussions and negotiations within the European Parliament.

“Millions of Europeans are in need of better treatments. We need to ensure that novel psychedelic treatments are being considered, as the science behind them highlights their immense potential” said MEP Mikuláš Peksa of the Czech Republic.

Members of the Action Group include Alviina Alametsä of Finland, a member of the country’s Green League political party; Robert Biedroń of Poland, a former Mayor of the city of Słupsk; Radka Maxová of the Czech Republic, who spoke today at a roundtable meeting in Belgium entitled: Vulnerabilities, Mental Health and Addictions; and Jarosław Duda, a Polish politician.

PAREA was established in June last year and is comprised of several member organizations involved with psychedelics including the Beckley Foundation, the European Brain Council, the Osmond Foundation (a founding member) and as of October last year, the European Psychiatric Association.

Read more: MindBio Therapeutics receives approval for LSD study for major depression

Read more: New survey aims to gather data on psychedelics use worldwide

The European Union has been a key influence in the field of clinical psychedelics in recent days. In March, the government in the Netherlands established an MDMA research commission to investigate the therapeutic properties of the psychedelic compound and its potential value within society.

In February, the United Kingdom’s Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) partnered with a Portuguese healthcare consortium to help establish a series of psychedelics clinics throughout Portugal.

A report from the market researcher Fairfield Consultancy Services in October last year indicated that the global market for psychedelics would be worth US$6.3 billion by 2026, ascending at a significant rate from its value of US$3.2 billion in 2021.


Follow Mugglehead on Twitter

Follow Rowan Dunne on Twitter






Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The Natural Medicine Health act will take effect on July 1


The study has been approved by the Clinical Trials Registry


The survey running until June 2 is sponsored by MAPS, Mind Medicine Australia, SABI Mind and Tiny


Research teams can receive up to $700K for an initial two-year phase to develop their studies, followed by up to $500K per year for...